Stay up to date on the latest oncology and nursing conferences.
RVd Plus ACST and Lenalidomide Maintenance Promote Efficacy in Newly Diagnosed Multiple MyelomaJune 8th 2022
Patients with multiple myeloma who received initial combination therapy with lenalidomide, bortezomib, and dexamethasone, plus autologous stem cell transplant, followed by lenalidomide maintenance, experienced improved progression-free survival.
Survival Benefit Observed With Nimotuzumab Plus Chemo in KRAS Wild-Type Advanced Pancreatic CancerJune 4th 2022
Patients with KRAS wild-type pancreatic cancer elicited a significant survival benefit with the addition of nimotuzumab to gemcitabine vs placebo plus gemcitabine in a phase 3 trial.
Avasopasem Represents Potential Mitigation Strategy for Radiotherapy-Induced Oral Mucositis in Head and Neck CancerJune 4th 2022
Avasopasem was associated with a significant reduction in severe oral mucositis in patients with locally nonmetastatic head and neck cancer undergoing chemoradiotherapy.
Black Patients With Metastatic Breast Cancer Experience More Hesitancy With Clinical Trial EnrollmentJune 3rd 2022
Although 83% of Black patients with metastatic breast cancer expressed interest in clinical trials, only 40% reported having a conversation about enrollment with their health care provider, highlighting one of many potential barriers to achieving clinical trial diversity.
Nurse Takeaways: How to Improve a Patient’s Experience With Sotorasib and Optimize NSCLC TreatmentMay 26th 2022
Oncology nurses present their experiences treating patients with sotorasib in the phase 1/2 CodeBreaK 100 trial and optimal symptom management strategies to improve patient outcomes with the drug.
Stephanie Jackson Discusses the Feasibility of a Discharge Lounge for Stem Cell Transplant UnitsMay 24th 2022
Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN, discusses how collaboration between an oncology unit and discharge lounge can improve discharge times for patients who have undergone stem cell transplantation.
Niraparib, Abiraterone, and Prednisone Triplet Shows Efficacy, Safety in mCRPC With HRR Gene AlterationsMay 19th 2022
The combination of PARP inhibition and androgen receptor targeted therapy was found to be tolerable in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations.
Patients With Metastatic Urothelial Carcinoma Achieve Superior Survival After Experiencing irAEs With PembrolizumabMay 17th 2022
In patients receiving immune checkpoint inhibition to treat their metastatic urothelial carcinoma, immune-related adverse effects may serve as a prognostic marker for progression-free and overall survival.
Regardless of Prior Local Treatment, Patients With mHSPC Achieve Improved Long-Term Survival With Enzalutamide Plus ADTMay 16th 2022
A post-hoc analysis of the phase 3 ARCHES found enzalutamide plus androgen deprivation therapy to be an effective treatment for patients with metastatic hormone-sensitive prostate cancer, no matter their history of prior local therapy.
Vitamin C Increases Chemotherapy Responses in Cisplatin-Ineligible Patients With Muscle-Invasive Bladder CancerMay 16th 2022
Patients with locally advanced muscle invasive bladder cancer may experience superior benefit from gemcitabine and carboplatin if the chemotherapy is co-administered with vitamin c.